Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1
- PMID: 19331584
- PMCID: PMC3052852
- DOI: 10.1086/598503
Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1
Conflict of interest statement
Figures
Comment on
-
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502. Clin Infect Dis. 2009. PMID: 19331585
References
-
- Hammer SM, Eron JJ, Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–70. - PubMed
-
- Palella FJ, Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34. - PubMed
-
- Geretti AM, Harrison L, Green H, et al. The effect of HIV-1 subtype on virological and immunological response to starting highly active antiretroviral therapy. Clin Infect Dis. 2009;48:1296–1305. (in this issue) - PubMed
-
- Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20:W13–23. - PubMed
-
- Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233:343–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
